Navigation Links
Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
Date:12/14/2011

p>

"Given Dr. Rastetter's industry experience in developing and commercializing highly innovative products, such as Rituxan®, we feel privileged that he will join our efforts in creating a world-leading therapeutics enterprise from our foundational science in adult stem cell biology," said John Mendlein, Ph.D., founder and Vice Chairman of Fate Therapeutics.  "Dr. Rastetter joins us at a transformational time as our innovative ProHema product advances closer to patient and commercialization reality.  His proven leadership in translating new therapeutic modalities into successful products enhances our team and our vision to deliver life-changing therapeutics to patients."

Dr. Rastetter also serves as the Chairman of Illumina, Inc., of Neurocrine Biosciences, Inc., and of Receptos, Inc., and is a partner in the venture capital firm Venrock.  Dr. Mendlein, in addition to his role as founder and Vice Chairman of Fate Therapeutics, is currently the Executive Chairman and CEO of aTyr Pharma.

About ProHema

ProHema is a first-in-class therapeutic consisting of pharmacologically-enhanced hematopoietic stem cells (HSC), where pharmacologic modulation imparts a greater than 20-fold up-regulation of key biological factors for enhanced HSC homing and proliferation.  Fate Therapeutics has completed a Phase 1b clinical study for ProHema in hematologic malignancy patients undergoing double-umbilical cord HSC transplant, and is exploring the therapeutic benefits of ProHema in other settings of HSC transplantation. The Company has submitted to the FDA a clinical protocol to evaluate ProHema in a single-cord blood allogeneic transplant setting, and intends to begin enrolling patients into that study within the next three months.

About Fate Therapeutics, Inc.

Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators (SCMs), biologic or small molecule compounds
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin
2. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
3. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
4. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
5. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
6. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
7. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
8. Aratana Therapeutics Completes $15 Million Series B Financing
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... 2014 The ability for organizations to ... will allow individuals to perform at the highest of ... employers looking to compete in this post–recession era. ... trend, as the sector increasingly focuses on the importance ... will have real results on the organization's development and ...
(Date:8/28/2014)... WA (PRWEB) August 28, 2014 Sterlitech ... Filtration’s polymeric membranes to its stable of products ... available molecular weight cut-offs and include membrane filters with ... steady increase in customer demand for our membrane process ... greater variety of flat sheet membranes,” explains Sterlitech President ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... Tecnalia Construction Unit, within the framework of its commitment ... cements that enable cutting direct CO2 emissions to the ... new ecological cement, as well as the techniques for ... the obtention of two patents, whose ownership is shared ...
... relies heavily on the performance and availability of ... Cluster FOREMOST project ensured that the advanced process ... node CMOS logic and 50nm DRAM memory technologies ... This project enabled key European players in semiconductor ...
... Cytomedix Inc (GTF) announces the following Webcast: , , , ... , , When:  July 20, ... Where:   http://www.investorcalendar.com/ClientPage.asp?ID=160316 , , ... on to the web at the address above. , , , ...
Cached Biology Technology:Tecnalia investigates ecological cement that cuts CO2 emissions by up to 100 percent 2European cooperation ensures global leadership in microelectronics 2European cooperation ensures global leadership in microelectronics 3European cooperation ensures global leadership in microelectronics 4Webcast Alert: Cytomedix Inc (GTF) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation 2
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research ... for the Genetics Society of America,s 27th Annual ... October 3, 2014 in Pacific Grove, California. ... of students, post doctorates and scientists from underrepresented ... community and to encourage the participation of young ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
(Date:8/28/2014)... method for delivering compounds that could positively ... AIDS may be possible, thanks to researchers ... A semi-soft vaginal suppository made from the ... the antiviral drug Tenofovir provides a woman-initiated, ... spread of sexually transmitted infections during unprotected ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... National Institutes of Health is launching the first ... for rare and neglected diseases. The $24 million ... for Rare and Neglected Diseases Program, or TRND. ... spring, is unusual because TRND creates a drug ...
... synthetic fragments of genetic material called small interfering RNA ... exciting new drug candidates can also induce a strong ... stimulates this undesirable immune activity, how to test for ... it are critical topics explored in a timely review ...
... “New Strategies for Optimizing CHO Performance,” to feature ... ZAP-CHO during BIO 2009 International Convention in Atlanta, ... / b3c newswire / – InVitria’s Director ... the performance enhancing features of ZAP-CHO, a new ...
Cached Biology News:NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5Strong immune response to new siRNA drugs in development may cause toxic side effects 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2
... The Helios gene gun system, 100-120 V, ... biomaterials into cells. This handheld device employs ... RNA-, and other biomaterial-coated gold microcarriers from ... cartridge directly into target cells. This system ...
... Mouse polyclonal antibody raised ... Immunogen: ... 94 a.a) partial recombinant protein ... Accession Number: NM_024721 ...
... Mouse polyclonal antibody raised ... Immunogen: ... 241 a.a) partial recombinant protein ... Accession Number: NM_004693 ...
... The binding specificity and signaling of ... known to be modified by alternative splicing--which ... GPCR SpliceArrays you can perform a classical ... detect the different alternatively spliced forms of ...
Biology Products: